News | June 03, 2022
GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
100% efficacy against severe Covid-19 disease and hospitalizations
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
Subscribe To Our Newsletter & Stay Updated
